Dernièrement…

Welcome @AmoebaNature as a featured exhibitor at the BioSolutions Conference & Expo!

Amoéba is an innovative #greentech company providing the industry with disruptive & sustainable solutions for key resource treatment. Learn more at http://ow.ly/icPi50Mzv8N

#BioSolutions

📣 Communiqué de presse : https://bit.ly/3RbfQHe
#Amoéba annonce l’annulation de l’émission de la 8° tranche optionnelle d’OCA et la signature d’un contrat avec Redbridge Debt and Treasury Advisory afin d’adapter sa stratégie financière aux enjeux de transformation industrielle

📣 Communiqué de presse : https://bit.ly/3X2hdKt
#Amoéba confirme son éligibilité au dispositif PEA-PME. Les #actions AMOEBA peuvent donc être intégrées dans les portefeuilles PEA PME, dédiés aux #investissements dans les #PME et #ETI selon les critères réglementaires.

🎥 @Fabrice Plasson, PDG d’#Amoéba, revient sur cette année exceptionnelle dans une vidéo dédiée au #bilan 2022 et aux #perspectives 2023. AMM, nouvelle usine, stratégie, plan de financement, tant de sujets abordés sur la chaîne #YouTube d’#Amoéba : https://bit.ly/3Wz75bz

Amoéba: US regulatory calendar update

Amoéba updates the regulatory calendar for both the biocide and biocontrol applications in the US.

Lyon (France), May 30, 2022 – 17h45 – AMOÉBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, updates the regulatory calendar for both the biocide and biocontrol applications in the US.

Application for authorization of the biocide in the United States

The application for approval of the biocidal active substance, the living amoeba Willaertia magna C2c Maky, and biocidal products containing it, filed in April 2021 with the U.S. Environmental Protection Agency (U.S. EPA), is still under review. The conclusions were, according to the legal deadline announced by the authority, expected by mid-2022. The U.S. EPA has requested an extension of the assessment period: the conclusions of the assessment should now be available in the second half of 2022.

Application for authorization of the biocontrol in the United States

The application for approval of the biocontrol active substance, the lysate of Willaertia magna C2c Maky, and the biocontrol products containing it, filed in October 2020 with the U.S. Environmental Protection Agency (EPA), is still under review. The conclusions were, according to the legal deadline announced by the authority, expected by the end of May 2022. The U.S. EPA has requested an extension of the assessment period: the conclusions of the assessment should now be available in the second half of 2022.